Is clinical endocannabinoid deficiency (CECD) a real condition?
Research-Based Answer
Clinical endocannabinoid deficiency (CECD) is a hypothesis proposed by Dr. Ethan Russo (2004, 2016) suggesting that conditions like migraine, fibromyalgia, and IBS may result from deficient endocannabinoid tone. The hypothesis has biological plausibility: (1) Migraine patients show lower CSF anandamide levels than controls. (2) Fibromyalgia patients show altered CB1 receptor expression. (3) All three conditions respond to treatments that enhance endocannabinoid signaling. However, CECD is not an established medical diagnosis. The evidence is largely indirect and correlational. No validated biomarker exists for endocannabinoid deficiency. The hypothesis is scientifically interesting and has generated useful research questions, but should not be used to justify cannabis treatment for these conditions without direct clinical evidence. It remains a hypothesis, not a confirmed pathophysiological mechanism.
This answer summarizes peer-reviewed research and is intended for educational purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before making any medical decisions.